文献速递前列腺癌

两基因mRNA尿液检测在初次前列腺活检前检测临床显著前列腺癌的多中心优化与验证

Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy.
PubMed 文献 · J Urol · 2019-07-08

研究纳入荷兰、法国和德国1955例初次前列腺活检男性,将尿液HOXC6和DLX1 mRNA与年龄、直肠指检、前列腺特异抗原密度结合建立临床模型,在715例PSA<10 ng/ml验证队列中AUC为0.82,灵敏度89%、特异度53%、阴性预测值95%,优于PCPTRC的AUC 0.70。

要点

  • 两基因尿液检测联合临床因素可对初次活检男性进行风险分层。
  • PSA<10 ng/ml验证队列AUC 0.82,灵敏度89%,阴性预测值95%。
  • PCPTRC版本2.0在PSA<10 ng/ml验证队列AUC为0.70。

核心结论

  • 针对血清PSA<10 ng/ml的初次活检患者优化的两基因尿液检测,在检测临床显著前列腺癌方面显示出高灵敏度和阴性预测值。
  • 这些数据支持使用该检测帮助指导初次前列腺活检决策。

研究设计与样本

  • 多中心研究,尿液样本来自荷兰、法国和德国的1955例初次前列腺活检男性,受试者分为训练队列和验证队列。
  • 对尿液HOXC6和DLX1 mRNA水平进行定量,并将RNA结果与其他危险因素结合,在PSA<10 ng/ml男性中优化临床模型以检测ISUP分级分组2级或以上前列腺癌。
  • 验证队列结果与PCPTRC版本2.0进行比较。

主要发现

  • 最佳临床模型包括尿液HOXC6和DLX1 mRNA水平、患者年龄、直肠指检和前列腺特异抗原密度(血清前列腺特异抗原/前列腺体积)。
  • 在715例PSA<10 ng/ml验证队列受试者中,AUC为0.82,灵敏度89%,特异度53%,阴性预测值95%;PCPTRC的AUC为0.70。
  • 包含所有PSA水平的916例完整验证队列中,AUC为0.85,灵敏度93%,特异度47%,阴性预测值95%;PCPTRC的AUC为0.76。

关键数值与推荐

  • PSA<10 ng/ml验证队列:两基因模型AUC 0.82,灵敏度89%,特异度53%,阴性预测值95%。
  • PSA<10 ng/ml验证队列:PCPTRC版本2.0的AUC为0.70。
  • 完整验证队列(916例,包含所有PSA水平):两基因模型AUC 0.85,灵敏度93%,特异度47%,阴性预测值95%。
  • 完整验证队列:PCPTRC版本2.0的AUC为0.76。

临床怎么用

  • 作者认为这些数据支持使用该检测帮助指导初次前列腺活检决策。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A 2-gene, urine based molecular test that combines mRNA biomarkers with clinical factors can risk stratify patients for clinically significant prostate cancer. To ensure the generalizability of assay results we optimized and validated the clinical model for men with serum prostate specific antigen less than 10 ng/ml who were undergoing initial prostate biopsy. MATERIALS AND METHODS: Urine samples were collected from 1,955 men from The Netherlands, France and Germany prior to an initial prostate biopsy and study subjects were divided into training and validation cohorts. Urinary HOXC6 and DLX1 mRNA levels were quantified and RNA results were then combined with other risk factors in a clinical model optimized to detect ISUP (International Society of Urological Pathology) Grade Group 2 or greater prostate cancer in men with prostate specific antigen less than 10 ng/ml. Results in the validation cohort were compared with the PCPTRC (Prostate Cancer Prevention Trial Risk Calculator), version 2.0. RESULTS: The optimal clinical model included urinary HOXC6 and DLX1 mRNA levels, patient age, digital rectal examination and prostate specific antigen density (serum prostate specific antigen/prostate volume). In the 715 validation cohort subjects with prostate specific antigen less than 10 ng/ml the AUC was 0.82 with 89% sensitivity, 53% specificity and 95% negative predictive value. The PCPTRC AUC was 0.70. The full validation cohort of 916 men including all prostate specific antigen levels yielded an AUC of 0.85 with 93% sensitivity, 47% specificity and 95% negative predictive value. The PCPTRC AUC was 0.76. CONCLUSIONS: The 2-gene based urine assay, which is optimized for biopsy naïve patients with serum prostate specific antigen less than 10 ng/ml, demonstrated high sensitivity and negative predictive value to detect clinically significant prostate cancer. These data support using the test to help guide initial prostate biopsy decisions.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Haese A, Trooskens G, Steyaert S, et al. Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy. J Urol. 2019. PMID: 31026217. doi:10.1097/JU.0000000000000293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。